aspirin has been researched along with eplerenone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Holman, JR; Jamieson, B; Lin, V | 1 |
| Chin, KL; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Swedberg, K; Turgonyi, E; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
2 review(s) available for aspirin and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Spironolactone; Ticlopidine | 2010 |
3 other study(ies) available for aspirin and eplerenone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Combination drug therapy after myocardial infarction. Early aldosterone blocking protects risk patients].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy, Combination; Eplerenone; Humans; Hypolipidemic Agents; Myocardial Infarction; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Time Factors | 2006 |
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Topics: Aged; Aspirin; Blood Pressure; Chronic Disease; Drug Interactions; Eplerenone; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Potassium; Proportional Hazards Models; Spironolactone; Stroke Volume | 2016 |